Project Grant R44DA061963
Award Date
6/15/25
Completion Date
5/31/27
Dollars Obligated
$1.6M
Federal Agency
National Institute on Drug Abuse
Awardee
Instanosis Inc. (CA5GQKREPCE4)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $386,452 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, CA. The grant supports the development of a rapid fingerstick diagnostic test for opioid and stimulant use disorders (OUD/STUD), which represent a significant public health crisis with over 107,000 overdose deaths reported in 2022. The project aims to create an innovative diagnostic...
The National Institute on Drug Abuse (NIDA) awarded a $1,539,426 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Serodopa Therapeutics Inc. to develop a novel intranasal formulation of a naloxone derivative for the reversal of opioid-induced respiratory depression caused by high-potency opioids such as fentanyl. The project aims to complete formulation development, preclinical toxicology and safety testing required to prepare an Investigational New Drug (IND)...
This Project Grant award from the National Institute of Justice (CFDA 16.560 - National Institute of Justice Research, Evaluation, and Development Project Grants) provides $434,500 to 9 Delta Analytical, LLC to develop two key products: 1) An inexpensive, visually-read testing device that allows rapid identification of fentanyl and other opioids in oral fluid samples, and 2) Environmentally-friendly laboratory confirmation procedures for analyzing the same oral fluid samples. The goal is to...
This $586,936 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of a low-cost, disposable urine test strip that can rapidly and quantitatively measure substance use disorder (SUD) medication drugs and their metabolites. The award recipient, Vitan-Biotech LLC, will create a point-of-use lateral flow assay (LFA) test strip that leverages innovative signal amplification technology to...
This $399,536 Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), aims to advance the development of non-opioid drug candidates to combat the opioid crisis. The grant supports two key objectives: Designing, synthesizing, and pharmacologically characterizing lead compounds and control compounds, including ADMET (absorption, distribution, metabolism, excretion, and toxicity) studies. Characterizing the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $643,948 to Labsys LLC to develop a transformative wearable patch device for continuous drug monitoring of opioid use disorders (CDM-MOUD). The device utilizes microneedle technology to monitor medication levels in the interstitial fluid, providing real-time insights into treatment effectiveness. The project aims to engineer an alpha...
The National Institute on Drug Abuse (NIDA) awarded a $591,752 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Oprems LLC, a for-profit organization located in Lake Forest, Illinois. The grant, awarded on September 15, 2024, will support the feasibility of integrating an electronic screening tool into a digital platform to identify risk of opioid misuse and overdose. The project aims to enhance the existing paper-based screening tool developed by the ONE...
This $475,500 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to develop new pharmacological approaches for reversing fentanyl overdose. The research aims to identify novel negative allosteric modulators (NAMs) of the mu opioid receptor that can attenuate the respiratory depression and other behaviors caused by fentanyl. The first goal is to screen a library of cannabidiol (CBD)...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $2,925,374 to Clear Scientific, LLC, a small for-profit company in Cambridge, Massachusetts, to develop a novel reversal agent for the treatment of overdose from the combination of the synthetic opioid fentanyl and the animal tranquilizer xylazine. The goal is to create a small-molecule sequestrant that can rapidly bind, inactivate, and clear...
This federal Project Grant award from the National Institute of Justice (CFDA 16.560 - National Institute of Justice Research, Evaluation, and Development Project Grants) provides $308,002 to Oakland University to develop an affordable, portable electrochemical sensor device for rapid, accurate detection of fentanyl and other opioids. The key objectives are to: 1) Fabricate a needle-based sensor, 2) Optimize the electrochemical signal analysis and detection for fentanyl, and 3) Test and...